Tirzepatide Research: Mechanism, Trials, and Cardiometabolic Outcomes | Tirzepatide
The short version
Tirzepatide research is unusually rich for a drug approved in 2022. The SURPASS programme covers five phase 3 trials in type 2 diabetes; the SURMOUNT programme covers obesity; SURPASS-CVOT ran a cardiovascular outcomes trial against an established comparator; SUMMIT tested tirzepatide in heart failure with preserved ejection fraction; SURMOUNT-OSA covered sleep apnea; SYNERGY-NASH addressed liver disease. This page reads the mechanism, the landmark glycaemic and weight trials, the cardiovascular and kidney data, and the safety meta-analyses. Every quantitative claim is cited. Evidence gaps are flagged as gaps.
Tirzepatide mechanism of action: dual receptor engagement
The Coskun et al. 2018 discovery paper established the mechanism: tirzepatide (LY3298176) activates both the GIP receptor and the GLP-1 receptor through a single acylated 39-amino-acid molecule. In vitro, it activated both receptor signalling pathways and improved glucose-dependent insulin secretion. In mice with chronic administration, it reduced body weight and food intake significantly more than a selective GLP-1 receptor agonist [1].
The 2020 Willard et al. characterisation added mechanistic depth: tirzepatide is an imbalanced dual agonist — it engages the GIP receptor more fully than the GLP-1 receptor, and it shows biased GLP-1 receptor signalling that favours cAMP generation over beta-arrestin recruitment [12]. Beta-arrestin1 is a protein that limits the insulin response to GLP-1 in primary islets; tirzepatide's biased agonism bypasses that limitation, enhancing insulin secretion relative to what a balanced GLP-1 agonist would produce.
GIP and GLP-1 receptors are expressed across the liver, muscle, adipose tissue, central nervous system, heart, immune system, and kidney [11]. That broad receptor distribution is the mechanistic basis for the cardiorenal effects observed in the clinical programme beyond glycaemic control and weight.
SURPASS: tirzepatide in type 2 diabetes
SURPASS-2 (n=1,879, 40 weeks, phase 3, open-label) was the first direct head-to-head trial of tirzepatide against semaglutide 1 mg in type 2 diabetes. HbA1c reductions at week 40 [2]:
- Tirzepatide 5 mg: -2.01 percentage points
- Tirzepatide 10 mg: -2.24 percentage points
- Tirzepatide 15 mg: -2.30 percentage points
- Semaglutide 1 mg: -1.86 percentage points
All three tirzepatide doses were non-inferior and statistically superior to semaglutide. Weight reductions were also greater with tirzepatide at all doses (treatment difference -1.9 kg at 5 mg, -3.6 kg at 10 mg, -5.5 kg at 15 mg) [2].
SURPASS-5 tested tirzepatide added to insulin glargine in type 2 diabetes inadequately controlled on basal insulin. All three tirzepatide doses produced significantly greater improvements in HbA1c and body weight versus placebo added to insulin glargine [13].
SURPASS-CVOT (ongoing, registered NCT04255433) is a cardiovascular outcomes trial comparing tirzepatide against dulaglutide 1.5 mg in adults with type 2 diabetes and established cardiovascular disease. Initial 2025 results were published in the New England Journal of Medicine [31].
SURMOUNT: tirzepatide weight loss results
SURMOUNT-1 (n=2,539, 72 weeks, phase 3, double-blind) enrolled adults with obesity or overweight plus complications but without type 2 diabetes. Mean weight changes: -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) versus -3.1% placebo. All doses superior to placebo [3].
SURMOUNT-5 (n=751, 72 weeks, phase 3b, open-label) compared tirzepatide at maximum tolerated dose (10 or 15 mg) versus semaglutide at maximum tolerated dose (1.7 or 2.4 mg). Tirzepatide: -20.2%; semaglutide: -13.7% (p < 0.001). Tirzepatide also produced greater reductions in waist circumference and higher proportions reaching ≥10%, ≥15%, ≥20%, and ≥25% weight loss [4].
SURMOUNT-OSA evaluated tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity. Significant reductions in the apnea-hypopnea index (AHI — the number of breathing events per hour of sleep) were observed alongside substantial weight reduction, forming the basis for the sleep apnea approval [14].
Tirzepatide vs semaglutide: the full comparison
Two datasets now directly compare tirzepatide and semaglutide. In type 2 diabetes (SURPASS-2): tirzepatide at all three fixed doses was superior to semaglutide 1 mg on HbA1c, and greater on weight at all doses [2]. In obesity without diabetes (SURMOUNT-5): tirzepatide at maximum tolerated dose was superior to semaglutide at maximum tolerated dose on percentage body weight change (-20.2% vs -13.7%) [4].
The two trials use different comparator structures (fixed dose vs maximum tolerated dose; closed-label vs open-label), so they answer slightly different questions. Together they establish that across two key populations, tirzepatide's dual receptor engagement produces clinically meaningfully larger outcomes than a GLP-1-only reference.
Several proposed mechanisms have been advanced for the difference: the GIPR-favouring imbalanced engagement, the biased GLP-1R cAMP signalling, the combined central appetite effects of both receptor pathways, and the additional tissue-level GIP receptor signalling in liver, adipose, and CNS [11][12]. Whether one mechanism dominates is not yet established.
Tirzepatide results: cardiometabolic expansion
Three trials beyond the diabetes and obesity programmes have produced notable tirzepatide results.
SURMIT (2025): Tirzepatide reduced heart-failure events and improved functional status in adults with heart failure with preserved ejection fraction (HFpEF — a form of heart failure in which the heart's pumping fraction stays normal) and obesity. Published in the New England Journal of Medicine [29].
SURPASS-4 kidney substudy: In adults with type 2 diabetes at high cardiovascular risk, tirzepatide produced slower eGFR (estimated glomerular filtration rate — a marker of kidney filtering capacity) decline and reduced albuminuria versus insulin glargine [5].
Blood pressure: A dedicated 24-hour ambulatory blood pressure monitoring study (de la Cruz-Concepcion 2024) found significant reductions in 24-hour ambulatory systolic blood pressure in adults with BMI ≥27 treated with tirzepatide [32].
SYNERGY-NASH: In adults with metabolic dysfunction-associated steatohepatitis (MASH — a progressive fatty-liver disease formerly called NASH), tirzepatide produced significant improvements in liver histology [30].
The pattern across these trials points to the same mechanism as the weight and glycaemic data: the broad tissue distribution of GIP and GLP-1 receptors translates dual receptor engagement into cardiometabolic effects that extend well beyond the pancreas.